Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Current Leases: 2019-2025

Historic Current Leases for Cartesian Therapeutics (RNAC) over the last 7 years, with Sep 2025 value amounting to $3.9 million.

  • Cartesian Therapeutics' Current Leases rose 39.93% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year increase of 39.93%. This contributed to the annual value of $2.9 million for FY2024, which is 31.63% up from last year.
  • According to the latest figures from Q3 2025, Cartesian Therapeutics' Current Leases is $3.9 million, which was up 2.27% from $3.8 million recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' Current Leases registered a high of $3.9 million during Q3 2025, and its lowest value of $942,000 during Q1 2021.
  • Its 3-year average for Current Leases is $2.6 million, with a median of $2.5 million in 2024.
  • Its Current Leases has fluctuated over the past 5 years, first slumped by 40.72% in 2021, then skyrocketed by 66.17% in 2025.
  • Cartesian Therapeutics' Current Leases (Quarterly) stood at $1.0 million in 2021, then skyrocketed by 53.29% to $1.6 million in 2022, then soared by 34.70% to $2.2 million in 2023, then surged by 31.63% to $2.9 million in 2024, then soared by 39.93% to $3.9 million in 2025.
  • Its Current Leases stands at $3.9 million for Q3 2025, versus $3.8 million for Q2 2025 and $3.7 million for Q1 2025.